Results 1 to 10 of about 499,052 (176)

Targeting WEE1 Kinase in Gynecological Malignancies [PDF]

Drug Design, Development and Therapy
Wenhao Zhang,1,2 Qingli Li,1,2,* Rutie Yin1,2,* 1Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Key Laboratory of Birth Defects and Related Diseases of ...
Zhang W, Li Q, Yin R
doaj   +8 more sources

WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma [PDF]

JCI Insight, 2022
CIC-DUX4 rearrangements define an aggressive and chemotherapy-insensitive subset of undifferentiated sarcomas. The CIC-DUX4 fusion drives oncogenesis through direct transcriptional upregulation of cell cycle and DNA replication genes.
Rovingaile Kriska M. Ponce, Nicholas J. Thomas, Nam Q. Bui, Tadashi Kondo, Ross A. Okimoto   +4 more
doaj   +5 more sources

GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer [PDF]

Cell Reports
Summary: Patients with small-cell lung cancer (SCLC) are in dire need of more effective therapeutic options. Frequent disruption of the G1 checkpoint in SCLC cells creates a dependency on the G2/M checkpoint to maintain genomic integrity.
Alexandros P. Drainas, Wen-Hao Hsu, Alec E. Dallas, Carson D. Poltorack, Jun W. Kim, Andy He, Garry L. Coles, Maya Baron, Michael C. Bassik, Julien Sage   +9 more
doaj   +3 more sources

WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy [PDF]

OncoImmunology, 2018
Intrinsic resistance to cytotoxic T-lymphocyte (CTL) killing limits responses to immune activating anti-cancer therapies. Here, we established that activation of the G2/M cell cycle checkpoint results in tumor cell cycle pause and protection from ...
Lillian Sun, Ellen Moore, Rose Berman, Paul E. Clavijo, Anthony Saleh, Zhong Chen, Carter Van Waes, John Davies, Jay Friedman, Clint T. Allen   +9 more
doaj   +3 more sources

Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy [PDF]

International Journal of Molecular Sciences, 2021
During the cell cycle, DNA suffers several lesions that need to be repaired prior to entry into mitosis to preserve genome integrity in daughter cells. Toward this aim, cells have developed complex enzymatic machinery, the so-called DNA damage response (DDR), which is able to repair DNA, temporarily stopping the cell cycle to provide more time to ...
Stefano Forte, Raffaella Giuffrida, Francesca Esposito   +2 more
exaly   +6 more sources

Pharmacological Inhibition of Wee1 Kinase Selectively Modulates the Voltage-Gated Na⁺ Channel 1.2 Macromolecular Complex [PDF]

Cells, 2021
Voltage-gated Na+ (Nav) channels are a primary molecular determinant of the action potential (AP). Despite the canonical role of the pore-forming α subunit in conferring this function, protein–protein interactions (PPI) between the Nav channel α subunit ...
Nolan M. Dvorak, Cynthia M. Tapia, Timothy J. Baumgartner, Jully Singh, Fernanda Laezza, Aditya K. Singh   +5 more
doaj   +2 more sources

Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1

Frontiers in Oncology, 2022
Cancer cells typically heavily rely on the G2/M checkpoint to survive endogenous and exogenous DNA damage, such as genotoxic stress due to genome instability or radiation and chemotherapy.
Amirali B. Bukhari, Gordon K. Chan, Armin M. Gamper   +2 more
doaj   +3 more sources

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors [PDF]

Frontiers in Oncology, 2022
In chronic myeloid leukemia (CML), Aurora kinase A and Polo like kinase 1 (PLK1), two serine-threonine kinases involved in the maintenance of genomic stability by preserving a functional G2/M checkpoint, have been implicated in BCR::ABL1-independent ...
Manuela Mancini, Sara De Santis, Cecilia Monaldi, Fausto Castagnetti, Fausto Castagnetti, Annalisa Lonetti, Samantha Bruno, Elisa Dan, Barbara Sinigaglia, Barbara Sinigaglia, Gianantonio Rosti, Michele Cavo, Michele Cavo, Gabriele Gugliotta, Simona Soverini   +14 more
doaj   +2 more sources

WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer [PDF]

EMBO Molecular Medicine
Molecular therapies targeting the EGFR/MAPK pathway have improved outcomes in colorectal cancer (CRC), yet acquired resistance remains a major clinical challenge. Oncogenic signaling can activate stress response pathways that sustain tumor survival under
Kristi Buzo, Laura Bizzozero, Marilena Lentini, Alena Opattova, Beatriz Hernández-Suárez, Michael Torres, Giulia Chiabotto, Clelia Nisticò, Giada De Lazzari, Eugenia R Zanella, Gaia Grasso, Elisa Mariella, Erika Durinikova, Michael Linnebacher, Andrea Sartore-Bianchi, Salvatore Siena, Livio Trusolino, Alberto Bardelli, Sabrina Arena   +18 more
doaj   +2 more sources

PKMYT1 in Cancer: Beyond Cell Cycle Checkpoints to Context-Dependent Therapeutic Vulnerability. [PDF]

Genes Chromosomes Cancer
ABSTRACT PKMYT1 has emerged as a promising therapeutic target distinguished by its tumor‐selective expression and essential role in replication stress management. Unlike WEE1, PKMYT1 is dispensable in normal cell cycles but critical for cancer cells coping with DNA damage, establishing a broad therapeutic window.
Li L, He B, Hao M, Liu Y, Song S, He R.
europepmc   +2 more sources